|
|
3721 Valley Centre Drive Suite 500
San Diego, CA 92130 USA
phone:858.480.0400
fax:858.509.1761
|
|
| Symbol |
SOMX |
| Exchange |
NASDAQ |
| Founded |
0 |
| Employees |
|
|
|
| www.somaxon.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Drugs for the areas of psychiatry and neurology. |
|
| Management |
| David F. Hale, Executive Chairman; Richard W. Pascoe, President and CEO; Susan E. Dub?, Senior Vice President, Corporate Development; Jeffrey W. Raser, Senior Vice President, Sales and Marketing; Philip Jochelson, M.D., Senior Vice President and Chief Medical Officer; James L'Italien, Ph.D., Senior Vice President, Regulatory Affairs and Quality Assurance; Meg M. McGilley, Vice President and Chief Financial Officer; Matthew W. Onaitis, Vice President and General Counsel; Brian T. Dorsey, Vice President, Product Development; Robert L. Jones, Vice President, Human Resources |
| |
|
|
|
|
|
|
|
| Keywords |
| psychiatry, neurology |
|
|
|
| Description |
|
Somaxon Pharmaceuticals, Inc. develops drugs in the areas of psychiatry and neurology including disorders of insomnia, impulse control, and involuntary movement. |
|
| Products / Services |
The company has in-licensed three products. Its lead product, SILENOR(tm) (doxepin HCl), is in Phase III clinical trials for the treatment of insomnia. Product nalmefene HCl is in a Phase II/III clinical trial for the treatment of pathological gambling and a Phase II clinical trial for smoking cessation. The company is also developing a new formulation of acamprosate Ca for the treatment of certain movement disorders.
|
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
